Johnson and Johnson (JNJ)

[DewDiligence]

FDA approves Tremfya (guselkumab) for psoriasis:

http://www.janssen.com/janssen-announces-us-fda-approval-tremfyatm-guselkumabfor-treatment-moderate-severe-plaque-psoriasis

Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration has approved TREMFYA (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

TREMFYA is the first and only approved biologic therapy that selectively blocks only IL-23, a cytokine that plays a key role in plaque psoriasis.

…TREMFYA is administered as a 100 mg subcutaneous injection every eight weeks, following two starter doses at weeks 0 and 4.

…Applications seeking approval in the European Union, Japan and other countries are currently under review.